The MarketWatch News Department was not involved in the creation of this content. -- Preliminary data showed Novavax's non-mRNA JN.1 COVID-19 vaccine induced lower frequency and severity of short-term ...

Earlier in January 2026, Novavax announced a non-exclusive license and option agreement granting Pfizer worldwide rights to ...

Novavax, Inc. (NASDAQ:NVAX) announced results Wednesday of the initial cohort of its COVID-19-Influenza Combination (CIC) and standalone trivalent hemagglutinin nanoparticle seasonal influenza (tNIV) ...

Novavax (NVAX) closed the most recent trading day at $9.22, moving -6.07% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 0.01%. On the other hand, ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Add Yahoo as a preferred source to see more of our stories on Google. Food and Drug Administration commissioner Martin Markary speaks during an event in the Roosevelt Room at the White House, Monday, ...

Peer-reviewed data shows Novavax's H5N1 vaccine candidate demonstrated immunogenicity against currently circulating variants following either single or two-dose administration Potential for single ...

In the latest close session, Novavax (NVAX) was down 1.97% at $9.71. This change lagged the S&P 500's 0.55% gain on the day.

Novavax, Inc. (NASDAQ:NAVX) stock traded higher on Wednesday. In an SEC filing, Novavax said, “We believe that our Biologics License Application (BLA) is approvable based on conversations with U.S.

Novavax (NVAX) closed the most recent trading day at $6.01, moving +0.17% from the previous trading session. This change outpaced the S&P 500's 2.36% loss on the day. Elsewhere, the Dow saw a ...

GAITHERSBURG, Md., Sept. 30, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced progress on its collaboration and license agreement (CLA) with Sanofi regarding Novavax's Matrix-M ® ...